Title for MeetingAbstracts
Alphabetical listing of titles
-
Asymptomatic, untreated perinatal HIV infection over 21 years after birth. An unique report, and psycho-sociological implications.
-
At drug plasma concentrations approximating the 50% inhibitory concentration, the HIV-1 reverse transcriptase inhibitor alpha-APA R18893 does not select for drug-resistant virus mutants in patients.
-
At least four HIV-1 genotypes circulate in Rosario, Argentina.
-
At risk infants: the cost of the first 18 months.
-
At risk sexual behaviour among in-school junior secondary one students in two Nigerian southwestern cities and its implications for the spread of HIV.
-
At the prison limits, a pilot experiment on integration in the housing projects: outgoing intermediary section (OIS) from Fresnes.
-
At-home care of terminal AIDS patients.
-
At-risk teens and HIV+ adults survey internal co-factors in HIV prevention of peers.
-
Atazanavir (ATV) QD and Efavirenz (EFV) QD with Fixed-Dose ZDV+3TC: Comparison of Antiviral Efficacy and Safety Through Wk 24 (AI424-034).
-
Atazanavir (ATV): Antiretroviral Efficacy in HIV-Infected Patients Co-Infected with Hepatitis B and/or C Viruses (HBV, HCV).
-
Atazanavir boosted with ritonavir in protease inhibitor-naive patients.
-
Atazanavir does not seem to have lipid lowering properties in patients with controlled HIV-infection and normal lipids.
-
Atazanavir Enhances Saquinavir Hard Gel Concentrations in a Ritonavir-Boosted Once Daily Regimen.
-
Atazanavir Plasma Levels Associated with Efficacy and Safety in Protease Inhibitor-experienced HIV-infected Patients.
-
Atazanavir Plus Saquinavir Once Daily Favorably Affects Total Cholesterol (TC), Fasting Triglyceride (TG), and Fasting LDL Cholesterol (LDL) Profiles in Patients Failing Prior Therapy (Trial AI424-009, Week 48).
-
Atazanavir-based salvage regimens in heavily-pretreated HIV-infected patients.
-
Atazanavir: A Once-Daily Protease Inhibitor with a Superior Lipid Profile: Results of Clinical Trials Beyond Week 48.
-
Atazanavir: A Summary of Two Pharmacokinetic Drug Interaction Studies in Healthy Subjects.
-
ATB[0,+], an Amino Acid Transporter, as a Drug Delivery System for Antiviral Agents in the Form of Prodrugs.
-
Atevirdine (ATV) pharmacokinetics (PK) and dosage requirements during a concentration-targeted (CT) phase I study (ACTG 199).
-
ATGWU's involvement in formulation and implementation of workplace HIV/AIDS policies and programmes.
-
Athena: A RCT examining the effectiveness of a home-based nursing intervention designed to improve adherence to Haart.
-
Atherogenic Lipid Profile and Cardiovascular Risk Factors in HIV-Infected Patients ("Netar Study").
-
Atherosclerosis risk assessment in HIV-infected patients: changes of carotid intima-media thickness over time.
-
Atipic presence of infection by Strongyloides stercoralis in patients with AIDS - Maceio - Alagoas - Brazil.
-
ATL146e (ATL), a New Selective Adenosine A[2A] Receptor Agonist, Improves Survival in E. coli O26:B6 Lipopolysaccharide (LPS)-induced Experimental Murine Endotoxemia.
-
ATL146e (ATL), a Selective A[2A] Adenosine Receptor Agonist, Combined with Ceftriaxone, Markedly Improves Survival in a Mouse Model of E. coli O26:B6 Sepsis.
-
Atopy,allergy and correlation with HIV disease in a group of seropositive patients.
-
Atorvastatin in the treatment of dyslipaemia related to antiretroviral therapy (ART).
-
Atorvastatin Inhibits Neutrophil Chemotaxis in Healthy Volunteers.